Cushing’s Syndrome Market- Competitive Landscape
Increase in research and development in 2016, which includes development of clinical trials for RECORLEV for the treatment of endogenous Cushing’s syndrome by Strongbrigde Biopharma plc is expected to create competition and also favor the growth between various manufacture to lead the market. The key players operating in Cushing’s syndrome market include Corcept Therapeutics Inc., HRA Pharma, Strongbridge Biopharma plc., and Novartis AG.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients